Crispr Therapeutics AG (CRSP)
Crispr Therapeutics: Prepare To Be Bored
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT, will generate revenue soon, with significant growth expected in 2025. The company's future potential lies in its pipeline for cardiovascular disease and cancer treatments, though these remain speculative.
1 Biotech Stock Down 62% to Buy and Hold
CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improvement.
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
3 Monster Biotech Stocks to Buy Before 2025
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
Crispr's Casgevy Launch: Promising Start, Uncertain Future
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns.
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future.
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
